Early mycological treatment failure in AIDS-associated cryptococcal meningitis

Area of Science:

• Infectious Diseases
• Immunology
• Clinical Medicine

Background:

• Cryptococcal meningitis is a severe opportunistic infection in individuals with Acquired Immunodeficiency Syndrome (AIDS).
• High morbidity and mortality rates are associated with cryptococcal meningitis in AIDS patients, despite treatment.

Purpose of the Study:

• To evaluate the outcomes of cryptococcal meningitis treatment in AIDS patients using amphotericin B plus flucytosine.
• To identify factors associated with treatment failure and early mortality.

Main Methods:

• A cohort of 236 AIDS patients with cryptococcal meningitis treated with amphotericin B and flucytosine was analyzed.
• Multivariate analyses were performed to identify predictors of treatment failure, defined by negative cerebrospinal fluid (CSF) cultures by day 14 and survival at 10 weeks.

Main Results:

• 12% of patients died within 2 weeks, and 26% died before 10 weeks; only 55% had negative CSF cultures at 10 weeks.
• CSF cryptococcal antigen titer, serum albumin, and CD4 cell count were strongly associated with failure to achieve negative CSF cultures by day 14.
• Patients without negative CSF cultures by day 14 had a fivefold increased odds of failure at 10 weeks (OR, 5.0; 95% CI, 2.2-10.9).

Conclusions:

• The prognosis for AIDS-related cryptococcal meningitis remains poor.
• Initial treatment, CSF antigen levels, immune status (CD4 count), and nutritional status (albumin) are key determinants of early outcomes.
• Improved initial therapies and management strategies addressing immune function and nutritional status are crucial to enhance patient outcomes.